PPLPHARMA.NSPPLPHARMA.NSNSE

Revenue (LTM)

$91.5B

+12.0% YoY

Net Income (LTM)

$911M

+411.4% YoY

Free Cash Flow

$2.3B

Revenue CAGR (5Y)

+11.7%

Marginsimproving

FCF$2.3B

Profitable

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Revenue	58,868	65,591↑11.4%	70,816↑8.0%	81,712↑15.4%	91,512↑12.0%
Gross Profit	38,132	13,803↓63.8%	10,980↓20.5%	49,095↑347.1%	59,195↑20.6%
Operating Income	22,455	3,736↓83.4%	-360↓109.6%	5,198↑1544.6%	36,121↑595.0%
Net Income	5,715	3,760↓34.2%	-1,865↓149.6%	178↑109.6%	911↑411.4%
EBITDA	12,970	12,599↓2.9%	8,464↓32.8%	13,668↑61.5%	14,040↑2.7%
EPS Diluted	4.70	3.11↓33.8%	-1.54↓149.5%	0.14↑109.1%	0.68↑385.7%

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Cash & Equivalents	1,467	2,281↑55.5%	1,956↓14.3%	3,568↑82.4%	5,015↑40.5%
Total Current Assets	17,675	40,672↑130.1%	48,355↑18.9%	54,645↑13.0%	57,970↑6.1%
Total Assets	57,567	127,970↑122.3%	145,226↑13.5%	153,118↑5.4%	156,776↑2.4%
Total Current Liabilities	14,717	30,333↑106.1%	38,431↑26.7%	43,693↑13.7%	37,663↓13.8%
Total Liabilities	16,561	61,004↑268.4%	77,491↑27.0%	74,004↓4.5%	75,521↑2.0%
Total Equity	41,006	66,966↑63.3%	67,735↑1.1%	79,114↑16.8%	81,255↑2.7%
Total Debt	1,743	41,279↑2268.8%	56,371↑36.6%	47,102↓16.4%	48,565↑3.1%
Net Debt	275	38,998↑14065.7%	54,415↑39.5%	43,533↓20.0%	43,550↑0.0%

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Operating Cash Flow	347	7,664↑2107.4%	4,839↓36.9%	10,045↑107.6%	8,923↓11.2%
Capital Expenditure	-581	-8,895↓1430.7%	-9,648↓8.5%	-7,120↑26.2%	-6,644↑6.7%
Free Cash Flow	-234	-1,231↓426.3%	-4,809↓290.7%	2,925↑160.8%	2,279↓22.1%
Stock-Based Comp	0	0	0	275	480↑74.7%
Net Change in Cash	1,460	-1,768↓221.1%	-320↑81.9%	1,660↑619.4%	-369↓122.2%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance